Spectral AI, Inc. (MDAI)
NASDAQ: MDAI · IEX Real-Time Price · USD
1.800
-0.090 (-4.76%)
Apr 19, 2024, 3:34 PM EDT - Market open
Company Description
Spectral AI, Inc. operates as an artificial intelligence (AI) company.
The company focuses on medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers.
Its products include DeepView, a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention.
The company is based in Dallas, Texas.
Spectral AI, Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Wensheng Fan |
Contact Details
Address: 2515 Mckinney Ave #1000 Dallas, Texas 75201 United States | |
| Phone | (212) 492-3000 |
| Website | spectral-ai.com |
Stock Details
| Ticker Symbol | MDAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001833498 |
| ISIN Number | US84757T1051 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Wensheng Fan | Co-Founder, Chief Innovation Strategist and Senior Advisor to the Chief Executive Officer |
| Vincent Stanley Capone | Chief Financial Officer, General Counsel and Corporate Secretary |
| Christine Marks | Vice President of Marketing and Commercialization |
| Stan Micek | Interim Chief Operating Officer |
| Dr. Jeffrey Thatcher Ph.D. | Chief Scientist |
| Dr. Jeffrey E. Carter F.A.C.S., M.D. | Chief Medical Consultant |
| Prof. Paul Chadwick | Executive Vice President of UK and EMEA |
| Jeremiah A. Sparks MBA | Chief Commercialization Officer |
| David Bronson | Financial Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | EFFECT | Notice of Effectiveness |
| Apr 10, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 8-K | Current Report |